Immune Therapeutics Competitors and Similar CompaniesClear all
Immune Therapeutics's competitors and similar companies include Oxurion, Merus, Biosearch Life and Aerie Pharmaceuticals.
 Immune Therapeutics Immune Therapeutics is a specialty pharmaceutical company involved in the manufacturing and distribution of immunotherapies. |  Oxurion Oxurion (formerly known as ThromboGenics) is a biopharmaceutical company developing treatments to preserve vision in patients with diseases affecting the back of the eye. |  Merus Merus is a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics with the goal of treating and potentially curing cancer patients. |  Biosearch Life Biosearch Life is a biotechnology company that provides probiotics, omega-3 fatty acids, and botanical extracts. |  Aerie Pharmaceuticals Aerie Pharmaceuticals is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye. | |
Founding Date | Founding Date 2012 | Founding Date 1991 | Founding Date 2003 | Founding Date 2000 | Founding Date 2005 |
Type | Type Public | Type Public | Type Public | Type Subsidiary | Type Public |
Tags | |||||
Locations | Locations Winter Park, US HQ Orlando, US | Locations Leuven, BE HQ Dublin 8, IE | Locations Utrecht, NL HQ Cambridge, US | Locations Granada, ES HQ Madrid, ES | Locations Irvine, US HQ Dublin, IE 千代田区, JP Henley On Thames, GB Bedminster, US Durham, US |
Employees | Employees 460% decrease | Employees 785% increase | Employees 260 | Employees 91 | Employees 3808% increase |
Valuation ($) | Valuation ($) 7.8 m | Valuation ($) 626.1 k | Valuation ($) 3.6 b | Valuation ($) N/A | Valuation ($) 722.2 m |
Financial | |||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) €555k (FY, 2025) | Revenue (est.) $36.1m (FY, 2024) | Revenue (est.) N/A | Revenue (est.) $194.1m (FY, 2021) |
Cost of goods | Cost of goods N/A | Cost of goods N/A | Cost of goods N/A | Cost of goods N/A | Cost of goods $26.8m (FY, 2021) |
Gross profit | Gross profit N/A | Gross profit €937k (FY, 2025) | Gross profit $36.1m (FY, 2024) | Gross profit N/A | Gross profit N/A |
Net income | Net income ($2.4m) (FY, 2023) | Net income (€3.7m) (FY, 2025) | Net income ($215.3m) (FY, 2024) | Net income N/A | Net income ($74.8m) (FY, 2021) |
Funding | |||||
Total funding raised | Total funding raised N/A | Total funding raised $ 3.9m | Total funding raised $ 149.3m | Total funding raised N/A | Total funding raised $ 388.6m |
For sources of this data, please see the company profile
View Company Profiles
Oxurion
HQ
Leuven, BE
Employees
78↑ 5% increase
Oxurion (formerly known as ThromboGenics) is a biopharmaceutical company developing treatments to preserve vision in patients with diseases affecting the back of the eye.
View companyMerus
HQ
Utrecht, NL
Employees
260
Merus is a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics with the goal of treating and potentially curing cancer patients.
View companyBiosearch Life
HQ
Granada, ES
Biosearch Life is a biotechnology company that provides probiotics, omega-3 fatty acids, and botanical extracts.
View companyAerie Pharmaceuticals
HQ
Irvine, US
Employees
380↑ 8% increase
Aerie Pharmaceuticals is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye.
View company